Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Manfred Hauben

Showing results (101-110 of 112) with videos related to

Pageof 12
Sort By:
Drug Safety|January 23, 2023
Correction to: Individual Case Safety Report Replication: An Analysis of Case Reporting Transmission NetworksJohn van Stekelenborg, Vijay Kara, Roman Haack, et al.
Blood|June 10, 2010
Identifying drugs that cause acute thrombocytopenia: an analysis using 3 distinct methodsJessica A Reese, Xiaoning Li, Manfred Hauben, et al.
International Journal of Medical Informatics|February 24, 2009
Influence of the MedDRA hierarchy on pharmacovigilance data mining resultsRonald K Pearson, Manfred Hauben, David I Goldsmith, et al.
Drug Safety|May 23, 2009
An evaluation of three signal-detection algorithms using a highly inclusive reference event databaseAlan M Hochberg, Manfred Hauben, Ronald K Pearson, et al.
Pharmacoepidemiology and Drug Safety|August 31, 2006
Accelerating statistical research in drug safetyWarren Bilker, Victor Gogolak, David Goldsmith, et al.
Drug Safety|July 7, 2017
Muscular Adverse Drug Reactions Associated with Proton Pump Inhibitors: A Disproportionality Analysis Using the Italian National Network of Pharmacovigilance DatabaseAlice Capogrosso Sansone, Irma Convertino, Maria Teresa Galiulo, et al.
Drug Safety|January 14, 2026
Perspective on Better Access to Data and Data Integration in Pharmacovigilance: Information from a Focus GroupFlorence van Hunsel, Samantha Lane, Dawn Cooper, et al.
Drug Safety|March 30, 2026
A Scoping Review of Case-Level Causality Assessment Tools Developed Between 2008 and 2023; Strengths, Weaknesses and Potential Future ImprovementsDawn Cooper, Mohammed Toseef Ansari, Taylor Aurelius, et al.
Drug Safety|October 20, 2005
Perspectives on the use of data mining in pharmaco-vigilanceJune Almenoff, Joseph M Tonning, A Lawrence Gould, et al.
Annals of the Rheumatic Diseases|August 8, 2020
Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world dataPhilip Mease, Christina Charles-Schoeman, Stanley Cohen, et al.
Pageof 12

Showing results (101-110 of 112) with videos related to

Sort By:
Pageof 12
Drug Safety|January 23, 2023
Correction to: Individual Case Safety Report Replication: An Analysis of Case Reporting Transmission NetworksJohn van Stekelenborg, Vijay Kara, Roman Haack, et al.
Blood|June 10, 2010
Identifying drugs that cause acute thrombocytopenia: an analysis using 3 distinct methodsJessica A Reese, Xiaoning Li, Manfred Hauben, et al.
International Journal of Medical Informatics|February 24, 2009
Influence of the MedDRA hierarchy on pharmacovigilance data mining resultsRonald K Pearson, Manfred Hauben, David I Goldsmith, et al.
Drug Safety|May 23, 2009
An evaluation of three signal-detection algorithms using a highly inclusive reference event databaseAlan M Hochberg, Manfred Hauben, Ronald K Pearson, et al.
Pharmacoepidemiology and Drug Safety|August 31, 2006
Accelerating statistical research in drug safetyWarren Bilker, Victor Gogolak, David Goldsmith, et al.
Drug Safety|July 7, 2017
Muscular Adverse Drug Reactions Associated with Proton Pump Inhibitors: A Disproportionality Analysis Using the Italian National Network of Pharmacovigilance DatabaseAlice Capogrosso Sansone, Irma Convertino, Maria Teresa Galiulo, et al.
Drug Safety|January 14, 2026
Perspective on Better Access to Data and Data Integration in Pharmacovigilance: Information from a Focus GroupFlorence van Hunsel, Samantha Lane, Dawn Cooper, et al.
Drug Safety|March 30, 2026
A Scoping Review of Case-Level Causality Assessment Tools Developed Between 2008 and 2023; Strengths, Weaknesses and Potential Future ImprovementsDawn Cooper, Mohammed Toseef Ansari, Taylor Aurelius, et al.
Drug Safety|October 20, 2005
Perspectives on the use of data mining in pharmaco-vigilanceJune Almenoff, Joseph M Tonning, A Lawrence Gould, et al.
Annals of the Rheumatic Diseases|August 8, 2020
Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world dataPhilip Mease, Christina Charles-Schoeman, Stanley Cohen, et al.
Pageof 12